Shandong Sino Pharmaceutical Technology Co., Ltd.

We are supplying all of our  foreign customers with Customized Pharmaceutical Formulations or Dosage Forms.

You can tell us any pharmaceutical product, no matter what it is that you want. And then we will give you a detailed solution as per your requirement.  

AOD-9604 (full name: Anti-Obesity Drug 9604, lipidemic peptide) is a synthetic 29-amino acid fragment (IGF-1 177-191) at the C-terminal of human insulin-like growth factor-1 (IGF-1), with CAS number 221231-10-3. The core functions are targeted fat reduction, promoting lipolysis, and inhibiting fat production, without insulin-like hypoglycemic or growth-promoting activities

Mechanism of action and application direction
1. Core mechanism of action

Activate the β3 adrenergic receptor in adipocytes, promote the decomposition of triglycerides (lipolysis), and increase energy consumption;
Inhibit the activity of lipoprotein lipase (LPL), and reduce the uptake and storage of fatty acids by fat cells;
Inhibit the differentiation of preadipocytes into mature adipocytes and block adipogenesis;
It targets white adipose tissue and has no significant effect on brown fat, muscle or bone.

2. Main research application scenarios
Experimental evidence for specific directions in the research field (animal/in vitro)

Obesity intervention can reduce body fat percentage by 15% to 20% in mouse models related to simple obesity, abdominal fat accumulation, and metabolic syndrome, without affecting body weight

Metabolic disease non-alcoholic fatty liver disease (NAFLD) reduces the fat content in the liver and improves liver function indicators

Post-exercise body fat management and muscle-fat ratio optimization in sports nutrition assist in enhancing fat loss efficiency without affecting muscle mass

Administration protocol and dosage
Route of administration, recommended dosage, frequency, applicable scenarios, precautions
Subcutaneous injection of 200 to 500μg each time, 2 to 3 times a day for routine fat loss studies, alternating injections in the abdomen and thigh. The effect is better when administered on an empty stomach
The combination of AOD-9604 300μg and MOTS-c 1mg once a day enhances metabolic regulation, synergistically activates lipolysis and energy metabolism, and reduces the dose of a single drug

The treatment course is 8 to 12 weeks per cycle. For long-term fat loss studies, it can be repeated 4 to 6 weeks after drug withdrawal. Continuous use should be avoided

Safety and precautions
1. Common adverse reactions

Local: Mild redness, swelling and pain at the injection site (incidence < 15%), mostly transient.
General symptoms: Occasional dizziness, fatigue and nausea (prone to occur when the dose is greater than 500μg per dose), which are relieved after reducing the dosage.
Rare: Hypoglycemia (incidence < 1%), associated with fasting injection, can be restored by supplementing sugar.

2. Contraindications and Use with caution

Absolute contraindications: People allergic to AOD-9604 or excipients, pregnant women/lactating women, and patients with hypothyroidism;
Use with caution: Patients with severe cardiovascular diseases, liver and kidney dysfunction, and diabetes (blood sugar monitoring is required);
Drug interactions: Avoid combination with β3 receptor agonists (such as mirabegron) and thyroxine to prevent an increase in cardiovascular burden.